EUVIMEDEUVIMED entdecken
Open Access

DNA Methylation Profiling Distinguishes Adamantinoma-Like Ewing Sarcoma From Conventional Ewing Sarcoma

Karen J Fritchie, Baptiste Ameline, Vanghelita Andrei, Christopher Griffith, Akeesha A Shah, Josephine K Dermawan, Matteo Trucco, Thomas Budd, Judith J Thangaiah, Jeremy Molligan, Rumeal D Whaley, Kelly Magliocca und 7 weitere

Modern Pathology · 2023-11 · 36 (11) · 100301

DOI: 10.1016/j.modpat.2023.100301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-11. Verfasst von Karen J Fritchie und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address: fritchk@ccf.org. Hauptthemen laut MEDLINE: Sarcoma, Ewing, Adamantinoma, Sarcoma. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adamantinoma-like Ewing sarcoma (ALES) has traditionally been considered a variant of Ewing sarcoma because it generally harbors EWSR1::FLI1 fusions despite showing diffuse positivity for keratins and p40. However, it has become increasingly recognized that different tumors can have identical translocations, including shared fusions between carcinomas and sarcomas, raising questions as to whether ALES might represent a separate entity. Using methylation profiling, we further explored the relationship between Ewing sarcoma and ALES. The archives of multiple institutions were searched for candidate cases of ALES. DNA methylation profiling was performed and results were compared to corresponding data from conventional Ewing sarcoma. Twelve cases of ALES (5 previously reported) were identified in 10 men and 2 women (aged 20-72 years; median age, 41.5 years). Cases included tumors arising in the parotid gland (3), sinonasal cavity (2), submandibular gland (2), thyroid gland (1), neck (1), gingiva (1), hypopharynx (1), and mandible (1). Histologic review consistently showed sheets and nests of basaloid cells within a fibromyxoid or hyalinized stroma. All tumors were positive for at least 1 keratin and CD99 expression, whereas all 10 cases tested were positive for p63 or p40; S100 protein expression was noted in 2 cases. Cases harbored either EWSR1::FLI1 fusions (n = 6), FUS::FLI1 fusions (n = 1), and/or EWSR1 rearrangements (n = 6). Methylation profiling was successful in 11/12 cases evaluated. Unsupervised clustering and dimensionality reduction (Uniform Manifold Approximation and Projection) of DNA methylation data revealed a distinct methylation cluster for all 11 cases, including the tumor with the FUS::FLI1 fusion, which clearly segregated them from the conventional Ewing sarcoma. Follow-up (n = 11, 1-154 months) revealed that 4 patients experienced recurrence and 6 developed metastatic disease. ALES demonstrates a distinct methylation signature from conventional Ewing sarcoma. This finding adds to the distinctive immunoprofile of ALES, suggesting that these 2 tumors should be considered distinct entities rather than histologic extremes of the same disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, EwingAdamantinomaSarcomaMaleHumansFemaleAdultDNA MethylationRNA-Binding Protein EWSGene RearrangementOncogene Proteins, Fusion

Stichwörter der Autor:innen

EWSR1Ewingadamantinomasarcoma

Substanzen

RNA-Binding Protein EWSOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address: fritchk@ccf.org.
  • Bone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital and University of Basel, Basel, Switzerland.
  • Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio.
  • Department of Pediatric Hematology-Oncology and Bone Marrow Transplant, Cleveland Clinic, Cleveland, Ohio.
  • Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Förderung

  • NCI NIH HHS

Zitieren

APA

Fritchie, K. J., Ameline, B., Andrei, V., Griffith, C., Shah, A. A., Dermawan, J. K., Trucco, M., Budd, T., Thangaiah, J. J., Molligan, J., Whaley, R. D., Magliocca, K., Azzato, E., van Zante, A., Jo, V., Xu, B., Bishop, J. A., Rooper, L., & Baumhoer, D. (2023). DNA Methylation Profiling Distinguishes Adamantinoma-Like Ewing Sarcoma From Conventional Ewing Sarcoma. Modern Pathology, 36(11), 100301. https://doi.org/10.1016/j.modpat.2023.100301

Vancouver

Fritchie KJ, Ameline B, Andrei V, Griffith C, Shah AA, Dermawan JK, et al. DNA Methylation Profiling Distinguishes Adamantinoma-Like Ewing Sarcoma From Conventional Ewing Sarcoma. Modern Pathology. 2023;36(11):100301. doi:10.1016/j.modpat.2023.100301

BibTeX
@article{Fritchie2023,
  author = {Fritchie, Karen J and Ameline, Baptiste and Andrei, Vanghelita and Griffith, Christopher and Shah, Akeesha A and Dermawan, Josephine K and Trucco, Matteo and Budd, Thomas and Thangaiah, Judith J and Molligan, Jeremy and Whaley, Rumeal D and Magliocca, Kelly and Azzato, Elizabeth and van Zante, Annemieke and Jo, Vickie and Xu, Bin and Bishop, Justin A and Rooper, Lisa and Baumhoer, Daniel},
  title = {DNA Methylation Profiling Distinguishes Adamantinoma-Like Ewing Sarcoma From Conventional Ewing Sarcoma},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {11},
  pages = {100301},
  doi = {10.1016/j.modpat.2023.100301}
}
Kostenlos starten →